Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 156 Jul 27 – Oct 24, 2026
- Disclosed funding
- $5.9B 121 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| GB Giraffe Bio develops biochemical reagents for mineral recovery. | $6.4M | Seed | Biotech | Argentina | Investors | |
| ST Soufflé TherapeuticsCompany profile Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure. Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure. | $135M | Series B | Biotech | United States | Investors | |
| RT RadioNano TherapeuticsCompany profile RadioNano Therapeutics develops boron-containing nanoparticle medicines for boron neutron capture therapy. RadioNano Therapeutics develops boron-containing nanoparticle medicines for boron neutron capture therapy. | Undisclosed | Series B first closeSeries B | Biotech | Japan | Investors | |
| M MOLCURECompany profile MOLCURE combines AI molecular design, simulation and laboratory experiments to help pharmaceutical and biotechnology partners discover and improve antibody and peptide candidates. MOLCURE combines AI molecular design, simulation and laboratory experiments to help pharmaceutical and biotechnology partners discover and improve antibody and peptide candidates. | Undisclosed | Strategic investment agreementUndisclosed | Biotech | Japan | Investors | |
| R RivercellCompany profile Rivercell builds experimental data infrastructure and AI models to predict how human cells respond to treatments. Rivercell builds experimental data infrastructure and AI models to predict how human cells respond to treatments. | $25M | Seed | Biotech | France | Investors | |
| ES ER Stress Research InstituteCompany profile ER Stress Research Institute develops drug candidates targeting cellular stress responses, including an oral small-molecule programme for diabetes. ER Stress Research Institute develops drug candidates targeting cellular stress responses, including an oral small-molecule programme for diabetes. | Undisclosed | Strategic investment agreementUndisclosed | Biotech | Japan | Investors | |
| WG WhiteLab GenomicsCompany profile WhiteLab Genomics uses AI to design genetic medicines and develop bio-assets for cell, RNA and DNA therapies. WhiteLab Genomics uses AI to design genetic medicines and develop bio-assets for cell, RNA and DNA therapies. | $26M | Series B | Biotech | United States | Investors | |
| AS Autopoiesis SciencesCompany profile Autopoiesis Sciences is developing AI research tools that help scientists plan and carry out scientific discovery. Autopoiesis Sciences is developing AI research tools that help scientists plan and carry out scientific discovery. | $11M | Seed | Biotech | — | Investors | |
| E French foodtech company making protein-rich ingredients from spirulina. | €15M | Series A financing package including non-dilutive and bank fundingSeries A | Biotech, Foodtech | France | Investors | |
| SB Sensible BiotechnologiesCompany profile A platform for designing and manufacturing naturally modified mRNA medicines. A platform for designing and manufacturing naturally modified mRNA medicines. | $47M | Series A | Biotech | United Kingdom | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 27, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
9rounds3led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
5rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.